STOKE THERAPEUTICS, INC. (STOK)
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
📈 **POSITIVE** • High confidence analysis (91%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business